Chinese Newcomers Look For Niche Immuno-Oncology Opportunities
Cervical Cancer, SCLC Eyed
Chinese pharma companies are continuing to pile into the already overcrowded domestic anti-PD-1/L1 sector in China, but despite the competition and regulatory tightening, the latecomers are looking for opportunities in areas such as cervical and small cell lung cancer with relatively fewer contenders.
You may also be interested in...
China Approves World’s First Bispecific IO Drug Amid PD-1/L1 Glut
Akeso’s PD-1/CTLA-4-targeting therapy cadonilimab has been the front-runner in the bispecific antibody field in China, leading about 50 other similar agents under development by domestic pharma firms. With a new conditional approval, it has also gained a head start over home-grown PD-1/L1 antibody rivals in the cervical cancer space.
China’s Top Regulator Upholds Tough Stance Against 'Redundant' Clinical Trials
China's Center for Drug Evaluation has issued fresh warnings that it will tighten reviews of anti-tumor drugs on the grounds that “redundant” development activities waste clinical resources.
Chinese ADC Developers Catch Up with Global Players In Advancing Key Payloads
Chinese pharma firms led by Kelun are moving fast to develop the next-generation of cytotoxic "warheads," a key component of antibody-drug conjugates, disclosed company executives at conference in Suzhou.